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ABSTRACT
Introduction Mechanical bowel preparation (MBP) prior 
to rectal surgery is widely used. Based on retrospective 
data many guidelines recommend mechanical and 
oral antibiotic bowel preparation (MOABP) to reduce 
postoperative complications and specifically surgical 
site infections (SSIs). The primary aim of this study is to 
examine whether MOABP reduces complications of rectal 
surgery.
Methods and analysis The MOBILE2 (Mechanical Bowel 
Preparation and Oral Antibiotics vs Mechanical Bowel 
Preparation Only Prior Rectal Surgery) trial is a multicentre, 
double- blinded, parallel group, superiority, randomised 
controlled trial comparing MOABP to MBP among patients 
scheduled for rectal surgery with colorectal or coloanal 
anastomosis. The patients randomised to the MOABP 
group receive 1 g neomycin and 1 g metronidazole two 
times on a day prior to surgery and patients randomised to 
the MBP group receive identical placebo. Based on power 
calculations, 604 patients will be enrolled in the study. The 
primary outcome is Comprehensive Complication Index 
within 30 days after surgery. Secondary outcomes are SSIs 
within 30 days after surgery, the number and classification 
of anastomosis dehiscences, the length of hospital stay, 
mortality within 90 days after surgery and the number 
of patients who received adjuvant treatment if needed. 
Tertiary outcomes are overall survival, disease- specific 
survival, recurrence- free survival and difference in quality- 
of- life before and 1 year after surgery. In addition, the 
microbiota differences in colon mucosa are analysed.
Ethics and dissemination The Ethics Committee of 
Helsinki University Hospital approved the study. The 
findings will be disseminated in peer- reviewed academic 
journals.
Trial registration number NCT04281667.
INTRODUCTION
There is a long history of research into the 
benefits of preparing the bowel before 
colorectal surgery.1 Decades ago, mechanical 
bowel preparation (MBP) was thought to 
reduce surgical site infections (SSIs) and 
the risk of anastomotic leakage. However, 
later evidence showed that cleansing of the 
bowel does not, in itself, reduce the quan-
tity of bacteria in the intestinal mucosa.2 
Thus it has been hypothesised that providing 
patient oral antibiotics could be beneficial 
in combination or after MBP, which would 
reduce the number of bacteria in the intes-
tinal mucosa. The theory proposes that the 
cleansing of the bowel simply allows the anti-
biotics to reach the mucosa.2 As early as 1973, 
Nichols et al published their small prospec-
tive, randomised controlled trial (RCT) 
Strengths and limitations of this study
 ► To our knowledge, there are no large prospective 
trials among patients with rectal resection and 
colorectal/coloanal anastomosis comparing me-
chanical and oral antibiotic bowel preparation with 
mechanical bowel preparation only.
 ► Appropriate subgroup analyses have been planned 
according to neoadjuvant treatment and height of 
the anastomoses.
 ► Routine postoperative abdominal imaging with per 
rectal contrast medium or sigmoidoscopy will be 
performed for all patients to ensure the healing of 
anastomosis.
 ► Analyses of microbiota will provide more data of ef-
fects of antibiotics on different bacteria in the colon-
ic mucosa and lumen. Microbiota characteristics will 
be correlated with the clinical data to link specific 
bacteria with the outcomes.
 ► The multicentre prospective study setting with 
double- blinding and randomisation will minimise the 
potential bias associated with previous retrospective 
studies.
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comprising only 20 patients comparing MBP to MBP with 
oral antibiotics (mechanical and oral antibiotic bowel 
preparation, MOABP).3 They focused mainly on micro-
bial changes inside the bowel and there was no significant 
reduction of SSIs in the MOABP group.3 Furthermore, 
another small prospective randomised trial from the 
1970s studied MOABP.4 It found MOABP to be beneficial 
in terms of SSI, but intravenous antibiotic prophylaxis was 
not used, and the rate of SSIs in the control group was 
43% which is not in line with contemporary numbers.4 A 
RCT containing mainly rectal resections (70%) reported 
that there were significantly less SSIs in patients under-
going MOABP (oral neomycin and metronidazole) than 
MBP alone.5 Ever since, studies questioning the bene-
fits of cleansing the bowel have been published.6 Until 
quite recently, several extensive retrospective series 
focusing on colorectal surgery have been published. In 
those studies, patients who underwent MOABP have 
been compared with patients who received no bowel 
preparation (NBP) before surgery. These studies have 
shown a significant difference in favour of the patients 
who received MOABP.7–10 According to an earlier meta- 
analysis, MOABP compared with NBP reduced SSIs, but 
not overall complications or anastomotic leakages.11 
Another meta- analysis included only RCTs, but since the 
RCTs comparing MOABP to NBP did not exist at the time, 
they performed an indirect comparison of these two and 
showed by network meta- analysis that MOABP reduced 
the rates of SSI compared with NBP.12
In the modern era with enhanced recovery after surgery 
(ERAS) protocols, there has not been RCTs until recently, 
as the MOBILE trial was published.13 In contrast to retro-
spective series, no difference was found between MOABP 
and NBP among patients undergoing colon resection 
in terms of SSIs or overall morbidity.13 Another recent 
study, the ORALEV trial among patients undergoing 
colon surgery, found a significant reduction in SSI rates 
in those receiving oral antibiotics comparing to patients 
not receiving oral antibiotics. However, no MBP was used 
in either group in the ORALEV trial.14
For rectal surgery, the situation is different; the risk of 
leakage is higher for low colorectal and coloanal anas-
tomoses, and on the other hand, a protective ostomy is 
often used. Usually, if protective ostomy is anticipated, 
MBP has been widely used to clean the section of bowel 
between the stoma and the anastomosis. At one point, a 
Cochrane review concluded that MBP offers no benefit 
in rectal surgery either.15 However, the GRECCAR study 
group showed that MBP reduces infectious complications 
after rectal surgery (34% vs 16%).16 The American Society 
of Colon and Rectal Surgeons updated their recommen-
dation in 2019; MOABP is typically recommended also 
for elective rectal resections (Grade of Recommenda-
tion: Strong recommendation based on moderate- quality 
evidence, 1B).17 The ERAS society concluded that the 
quality of evidence is low, yet recommending oral anti-
biotics in addition to MBP, and furthermore concluding 
that oral antibiotics should not be given if MBP is not 
performed.18 There are no high- quality RCTs comparing 
MOABP to MBP including only patients undergoing 
rectal surgery.
This multicentre prospective randomised MOBILE2 
trial compares MOABP to MBP in patients undergoing 
rectal surgery. The aim of the study is to examine if oral 
antibiotics reduce the overall complications, SSIs or anas-
tomotic leakages after rectal surgery, and also if there are 
any adverse effects related to the oral antibiotics.
METHODS AND ANALYSIS
Study design
The MOBILE2 trial is a multicentre, double- blinded, 
parallel group, randomised superiority trial comparing 
MOABP with MBP in patients with rectal cancer sched-
uled for anterior rectal resection with planned colorectal 
or coloanal anastomosis. The study is carried out in 
three Finnish university hospitals (Helsinki, Turku and 
Tampere University Hospitals) with an option to include 
more centres along the trial. A flowchart of the trial is 
shown in figure 1.
Inclusion criteria
Patients scheduled for an anterior resection (resection of 
the rectum and performing colorectal or coloanal anas-
tomosis) due to a rectal tumour are eligible for the study. 
Tumours 15 cm or less from anal verge at MRI are consid-
ered as rectal tumours.
Exclusion criteria
The exclusion criteria are: (1) emergency surgery, (2) 
bowel obstruction before the surgery (MBP not possible), 
(3) ostomy created before the rectal surgery, (4) any other 
reason preventing MBP, (5) allergy to the antibiotics used 
in the study, (6) age <18 or (7) inadequate ability to coop-
erate. Postrandomisation exclusion criteria (patients will 
be excluded from the analysis if even one of these condi-
tions is met): (1) the surgery was not performed, (2) the 
rectal resection was not performed or (3) colorectal/
coloanal anastomosis was not created (eg, an end colos-
tomy was performed instead).
Trial intervention
MOABP group: bowel preparation using MBP and oral 
antibiotics.
MBP group: Bowel preparation using MBP and placebo.
The MBP is performed using polyethylene glycol 
(PEG). The patients drink 2 L of PEG and 1 L of clear 
fluids of the patient’s choice. The MBP can be started 
2 days before the surgery at 15:00 and must be completed 
by 15:00 on a day prior to the surgery. Thereafter, the 
patients take 1 g of neomycin or placebo orally at 15:00 
and 23:00 and 1 g of metronidazole or placebo orally at 
15:00 and 23:00. Patients receive perioperative prophy-
lactic intravenous antibiotics (cefuroxime 1.5 g, metro-
nidazole 500 mg) approximately 1 hour before surgery. 
The intravenous antibiotics are repeated if surgery is still 
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ongoing 3 hours after the first intravenous dose. Diverting 
ostomy is used in cases of low colorectal or coloanal anas-
tomosis (<6 cm from anal verge) or if there is leakage in 
the intraoperative air leak test or some other reason why 
surgeon considers diverting ostomy necessary.
Microbiota analysis
Faecal samples as well as biopsies of the colonic mucosa 
are collected from the patients randomised at Helsinki 
University Hospital. Samples are taken at the plan-
ning visit, at the surgery and 6 and 12 months after the 
surgery. Biopsies are collected directly in RNALater solu-
tion and stored at −20°C and faecal samples are stored 
at –80°C until analysis. The intestinal microbiota analyses 
are performed with established protocols in use in the 
Human Microbiome Research Program, University of 
Helsinki, as described previously.19 The primary analysis 
method is high- throughput sequencing of the 16S rRNA 
gene amplicons to assess the taxonomic composition 
and diversity of bacterial population. Based on this infor-
mation, a more detailed analysis by using metagenomic 
sequencing can be considered.
Randomisation procedure, stratification and masking
The patients are individually randomised 1:1 to MOABP 
group and MBP group. The randomisation sequence 
is generated with a computer using variable block size. 
Based on the randomisation sequence, antibiotics or 
placebo are packed at Helsinki University Hospital’s phar-
macy’s clinical trials unit in numerically numbered vials, 
which are grouped based on stratification. No person 
outside the pharmacy’s clinical trial unit has access to 
randomisation sequence or knows whether the vials 
contain placebo or antibiotics. Pharmacy’s clinical trial 
unit is not involved in the trial, except for producing and 
packing of the study medicine and placebo. Placebos are 
identical to oral antibiotics. The surgeon responsible for 
operation (or if absent, another surgeon at the unit) will 
obtain the informed consent. Allocation will take place at 
the preoperative appointment, after the patient has given 
their written consent to participate in the study (model 
consent form in Finnish: online supplemental appendix 
1). The patient is allocated by giving a vial from correct 
stratification group to the patient in numerical order.
The patient population is stratified for centre as well as 
according to the distance of the lower edge of the tumour 
from the anal verge (measured from rectal MRI) and 
the preoperative treatment they receive. Four different 
stratification groups are created for each participating 
centre: group A—<10 cm from anal verge, no preopera-
tive treatment or short course radiotherapy (SCRT) with 
immediate surgery; group B—<10 cm from anal verge, 
long course chemoradiotherapy (LCCRT) or SCRT with 
long waiting time; group C—≥10 cm from anal verge, no 
preoperative treatment or SCRT with immediate surgery 
and group D—≥10 cm from anal verge, LCCRT or SCRT 
with long waiting time.
The study is double- blinded. Patients, treating physi-
cians, ward nurses, data collectors and outcome analy-
sers are blinded to the allocated intervention. Once all 
the data have been collected and is in the analysis phase, 
patients will be sorted to groups A and B, but these will 
not yet be connected to whether the patient received a 
placebo or antibiotics. Only after the results have been 
analysed for the main and secondary outcomes will the 
blinding be completely eliminated. The patients undergo 
MBP and take their medication either at the ward or at 
home, according to the nurses’ instructions. Emergency 
envelopes will be stored at the ward, at a specific marked 
location, in case information about which medicine the 
patient has received is suddenly needed during treatment.
Figure 1 Flowchart of patient recruitment and randomisation. MBP, mechanical bowel preparation.
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Outcomes
The primary outcome is Comprehensive Complica-
tion Index (CCI) within 30 days after surgery.20 The 
secondary outcomes are (1) SSI within 30 days after 
surgery (according to the Centers for Disease and 
Control and Prevention criteria),21 including superfi-
cial incisional infection, deep incisional infection and 
organ/space infection, (2) the number and classifica-
tion of anastomosis dehiscence within 30 days of proce-
dure, (3) the length of hospital stay, (4) mortality within 
90 days after surgery (any cause) and (5) the number 
of patients who received adjuvant treatment divided by 
the number of patients that needed it within 6 months 
of the procedure. Adjuvant therapy indications follow 
the national recommendation of colorectal cancer treat-
ment.22 Tertiary outcomes (long- term follow- up) are (1) 
5- year overall survival, (2) 5- year disease- specific survival, 
(3) 5- year recurrence- free survival and (4) difference in 
quality- of- life questionnaire (36- Item Short Form Survey 
(SF-36), Quality of Life Questionnaire Core 30 (QLQ- 
C30), Quality of Life Questionnaire Colorectal 29 (QLQ- 
CR29), Low Anterior Resection Syndrome (LARS) scores 
before the surgery and 1 year after the surgery). Potential 
adverse effects of antibiotics (diarrhoea, Clostridium diffi-
cile infections or allergic reactions) will be collected.
Sample size calculation
In Helsinki University Hospital, the number of leakages/
abscesses related to low anterior resections performed 
in 2005–2011 was 12.8%, but minor wound complica-
tions were not reported.23 In our previous randomised 
MOBILE study comparing MOABP to NBP, patients 
undergoing colon resection had leakage/abscess rate of 
approximately 6%–8% and a CCI of 9–10 with SD 13–16.13 
Based on these figures, we estimate that the CCI is higher 
in rectal surgery than in colon surgery and the SD may 
also be higher. Sample size was calculated with the aim of 
showing a difference of 5 CCI points between the groups 
(hypothesis: 12.5 points in the MOABP group, 17.5 points 
in the MBP group). The SD is estimated to be 18 in both 
groups. With a power of 90% and a margin of error of 
5%, 574 patients need to be recruited (Willcoxon- Mann- 
Whitney test). About 5% of patients are estimated to 
become lost to follow- up, resulting in a final sample size 
of 604 patients.
Follow-Up
Normal postrectal surgery follow- up will be scheduled. At 
6–8 weeks after surgery, the patients will have an abdom-
inal imaging with per rectal contrast medium or, alterna-
tively, a sigmoidoscopy. At this time, it is checked whether 
the patient has experienced any SSIs, other complica-
tions, reoperations or died. With regard to long- term 
outcomes (tertiary outcomes), recurrences are checked 
from patient records and, if necessary, by ordering patient 
records from other hospitals, and furthermore the 
patient can be contacted by letter or telephone if needed. 
Patients will also be asked to complete quality- of- life 
questionnaires (SF-36, QLQ- C30, QLQ- CR29) before 
surgery and at 1- year after surgery.
Data collection and statistical analysis plan
Data will be collected by using paper case report forms by 
the colorectal surgeons responsible for patient care. The 
data for these forms are manually transferred to electron-
ical form. Only the study personnel will have access to final 
trial dataset. The study personnel have signed the confi-
dentiality agreement of study documents. Statistical anal-
yses are made with SPSS software. The primary outcome 
will be analysed using either the Mann- Whitney U test or 
the t- test, bootstrapped or log- transformed if necessary. 
Secondary outcomes will be analysed using either the 
t- test or the Mann- Whitney U test for continuous vari-
ables, depending on the distribution, and using χ2 or 
Fisher’s exact test for categorical variables. If necessary, 
log- transformation can be performed on non- normally 
distributed continuous variables, or a bootstrapped t- test 
can be used. A more detailed classification of SSIs will 
be reported (superficial, deep, organ/space). Tertiary 
outcomes will be analysed separately at a later date, when 
at least 1- year (for QOL) or 5- year follow- up (survival 
analyses) is available for all patients. Kaplan- Meier and 
the log- rank test will be used for survival analyses.
The following subgroup analyses will be performed 
for primary outcome and first secondary outcome (SSIs 
within 30 days): (1) tumour location (lower edge < or 
≥10 cm from anal verge, based on pre- op MRI), (2) long- 
term chemoradiotherapy before the surgery (yes/no), 
(3) protective ostomy (yes/no) and (4) surgical approach 
(minimally- invasive/open surgery).
Schedule
The treatment of rectal cancers in Southern Finland has 
been centralised to Helsinki University Hospital. About 
300 rectal cancer surgeries take place at the centre annu-
ally. Other research locations include Turku University 
Hospital and Tampere University Hospital. At least 2/3 of 
the rectal cancer operations are performed with primary 
anastomosis. Thus approximately 300 patients will be 
recruited annually and the estimated time for recruit-
ment is 2 years. The recruitment started on March 2020. 
After completing the recruitment of patients, the data will 
be analysed and reported in international peer- reviewed 
journal by the study team.
Patient and public involvement
Patients were not involved in the design of the study or 
assessment of the burden of the interventions. On recruit-
ment, patients are informed of the current knowledge on 
bowel preparation prior rectal resection. The risks and 
benefits of the trial intervention are explained to the 
patients.
Ethics and dissemination
The study will be conducted in accordance with the prin-
ciples of Declaration of Helsinki and ‘good clinical prac-
tice’ certification is demanded for all the study personnel. 
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The research is defined as clinical drug trial. The 
research plan has been evaluated by the Finnish National 
Committee on Medical Research Ethics (TUKIJA) and 
Finnish Medicines Agency (FIMEA) has been notified. 
The EUDRA CT number for the clinical drug trials has 
been applied (No 2018-004355-20). The research plan 
was further approved by the local ethics committee of 
Helsinki University Hospital and in each participating 
centres’ institutional review board (Helsinki University 
Hospital, Tampere University Hospital and Turku Univer-
sity Hospital). The trial has been registered at  Clinical-
Trials. gov (NCT04281667) before its initiation. The study 
is monitored by Clinical Research Institute HUCH (HYKS 
Instituutti). Monitoring is performed in accordance 
with currently valid rules and regulations, Good Clinical 
Practice.
DISCUSSION
While American Society of Colon and Rectum Surgeons 
recommends using MOABP for all colorectal operations, 
there is no randomised controlled evidence supporting 
the recommendation.17 In fact, in 2017 the European 
Society of Coloproctology collaborating group found out 
that only 17% of a large cohort of patients with colorectal 
cancer mainly in Europe received MOABP before 
colorectal resection.24 Another survey from Europe 
found out that MOABP was used in 6%–19% of the cases 
by European surgeon responders,25 while nearly 80% of 
surgeons in the USA reported routine use of MOABP.26
In the retrospective analysis of the 2015 American 
College of Surgeons National Surgical Quality Improve-
ment Program database comparing the four strategies in 
(MOABP, oral antibiotics alone, MBP alone, no prepa-
ration), MOABP was associated with the greatest risk 
reduction in SSIs and anastomotic leak when used prior 
to elective left- sided restorative colorectal surgery with 
pelvic anastomosis with and without faecal diversion in 
both laparoscopic and open setting.12
In a Canadian retrospective study of consecutive series 
of patients undergoing rectal surgery, MOABP with 
neomycin and metronidazole was associated with a signif-
icant reduction in superficial SSIs but not in organ/ space 
infections.27
After commencing the MOBILE2 trial, a trial from 
Russia was published, where patients undergoing rectal 
surgery were randomised to MOABP or MBP. The study 
reported a statistical difference in in SSIs favouring 
MOABP, but the study included only 116 patients, metro-
nidazole was not included in the intravenous antibiotic 
prophylaxis, the study was not blinded and patients with 
no bowel anastomosis were included.28
The SELECT trial compared prospectively selective 
decontamination of digestive tract (SDD) with an oral 
suspension containing amphotericin B, colistin sulphate 
and tobramycin to no decontamination.29 The patients 
with left colectomy received MBP, but patients under-
going right colectomy did not. Overall rate of infectious 
complications was smaller in SDD group, but no differ-
ence was noted in the anastomotic dehiscence rates. The 
results were not reported according to the side of colec-
tomy, and it remains unclear whether the SDD affects 
right- sided versus left- sided colectomies uniformly. By 
contrast the subgroup analysis of MOBILE trial reported 
no difference in SSIs either right or left colectomy.30
Although being a large multicentre trial, the study is 
limited by its sample size, which may not be sufficient 
for detecting subtle differences in the outcomes or in 
subgroup analyses. The study also includes both open and 
laparoscopic approaches, and results might not be gener-
alisable to other centres where this ratio differs from the 
trial significantly. On the other hand, this is a double- 
blinded placebo- controlled multicenter randomised trial 
providing the highest level of evidence on the subject.
There is a similar, although smaller, RCT to the 
MOBILE2 recruiting at the moment in France 
(PREPACOL2, NCT03491540) and we are also looking 
forward to their results in the future.
Finally, there seems to be many retrospective analyses, 
meta- analyses of the retrospective series, expert opinions 
and recommendations, but little high- quality evidence 
on the role of oral antibiotic preparation before rectal 
surgery.
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